CI 10-Q Quarterly Report March 31, 2024 | Alphaminr
ALPHAMINR

CI 10-Q Quarter ended March 31, 2024

Balance Sheet
Cash Flow
Income Statement
Debt
TABLE OF CONTENTS
Part IprintItem 1. Financial StatementsprintNote 1 Description Of BusinessprintNote 2 Summary Of Significant Accounting PoliciesprintNote 3 Accounts Receivable, NetprintNote 4 Supplier Finance ProgramprintNote 5 Assets and Liabilities Of Businesses Held For SaleprintNote 6 Earnings Per ShareprintNote 7 DebtprintNote 8 Common and Preferred StockprintNote 9 Insurance and Contractholder LiabilitiesprintNote 10 ReinsuranceprintNote 11 InvestmentsprintNote 12 Fair Value MeasurementsprintNote 13 Variable Interest EntitiesprintNote 14 Accumulated Other Comprehensive Income (loss)printNote 15 Income TaxesprintNote 16 Contingencies and Other MattersprintNote 17 Segment InformationprintItem 3. Quantitative and Qualitative Disclosures About Market RiskprintItem 4. Controls and ProceduresprintPart II. Other InformationprintPart IIprintItem 1. Legal ProceedingsprintItem 1A. Risk FactorsprintItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsprintItem 5. Other InformationprintItem 6. Exhibitsprint

Exhibits

3.1 Restated Certificate of Incorporation of The Cigna Group Filed by the registrant as Exhibit 3.1 to the Quarterly Report on Form 10-Q for the period ended June 30, 2023 and incorporated herein by reference. 3.2 Amended and Restated By-laws of The Cigna Group Filed by the registrant as Exhibit 3.3 to the Current Report on Form 8-K on February 13, 2023 and incorporated herein by reference. 4.1 Supplemental Indenture No. 7, dated as of February 13, 2024,between The Cigna Group and U.S. Bank Trust Company, National Association, as trustee Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on February 13, 2024 and incorporated herein by reference. 10.1 Offer Letter for Eric P. Palmer dated January 16, 2024 Filed by the registrant as Exhibit 10.23 to the Annual Report on Form 10-K for the period ended December 31, 2023 and incorporated herein by reference. 10.2 Offer letter for Brian Evanko dated January 16, 2024 Filed by the registrant as Exhibit 10.26 to the Annual Report on Form 10-K for the period ended December 31, 2023 and incorporated herein by reference. 31.1 Certification of Chief Executive Officer of The Cigna Group pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 Filed herewith. 31.2 Certification of Chief Financial Officer of The Cigna Group pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 Filed herewith. 32.1 Certification of Chief Executive Officer of The Cigna Group pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350 Furnished herewith. 32.2 Certification of Chief Financial Officer of The Cigna Group pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350 Furnished herewith.